News - 29 Jul `14Clinuvel receives takeover offer from a notorious short seller

New

Clinuvel receives takeover offer from a notorious short seller

Clinuvel Pharmaceuticals, drug developer for skin diseases from Melbourne, has received an unsolicited $95 million takeover offer from a controversial biotech company Retrophin, soon after sudden passing of Clinuvel's long time director Jack Wood. 

On behalf of VRF management, we offer our sincere condolences to Jack's wife and family. Jack Wood was a remarkable person with a vision, big heart and brilliant sense of humor. Clinuvel is awaiting clearance from the European drug regulator for the use of its drug Scenesse in the treatment of a rare skin disease Erythropoietic Protoporphyria and potentially, in vitiligo. 

Once a notorious short seller with loud public pressure, Reptophin's CEO Martin Shkreli now aims at drugs for ultra-rare and dangerous conditions. Clinuvel has appointed an advisory firm in the defense against the hostile offer.



      FAQOther Questions

      • How can I cure vitiligo?

        Right now, there is no universal "cure," but we have entered a new era of treatment. Today, managing vitiligo isn’t just about "hiding" it; it’s about sophisticated science that...

      • Vitiligo trials for kids: basics for the parents

        Pediatric vitiligo trials · The basics Two parallel studies are evaluating investigational use of ruxolitinib cream in young children — researchers are still finding out how wel...

      • Any link between vitiligo and military service?

        While there isn't specific research directly linking military service to the onset of vitiligo, it's critical to comprehend that vitiligo is a multifaceted disorder influenced b...